Showing results (101-110 of 141) with videos related to
Sort By:
Pageof 15
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2019
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T CellsSareetha Kailayangiri, Bianca Altvater, Stefanie Lesch, et al.Anticancer Research|October 28, 2025
Osteosarcoma of the Diaphysis: A Report from the Cooperative Osteosarcoma Study Group (COSS)Stefan S Bielack, Claudia Blattmann, Leo Kager, et al.Journal of Hematology & Oncology|January 17, 2025
Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adultsMaike Breidenbach, Peter Bader, Andishe Attarbaschi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid CancersLena Fischer-Riepe, Sareetha Kailayangiri, Katharina Zimmermann, et al.European Journal of Cancer (Oxford, England : 1990)|October 3, 2022
Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS)Stefan S Bielack, Claudia Blattmann, Arndt Borkhardt, et al.Leukemia|April 26, 2022
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international studyElad Jacoby, Sara Ghorashian, Britta Vormoor, et al.British Journal of Haematology|August 4, 2017
Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapyMichaela Kuhlen, Kirsten Bleckmann, Anja Möricke, et al.Frontiers in Immunology|April 11, 2022
GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18Wolfgang Glienke, Anna Christina Dragon, Katharina Zimmermann, et al.Leukemia|March 8, 2019
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.Haematologica|May 19, 2018
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB studyNatasha K A van Eijkelenburg, Mareike Rasche, Essam Ghazaly, et al.Pageof 15